1
|
Qiu X, Ma C, Luo Z, Zhang Y, Kang J, Zhu D, Wang Z, Li L, Wei Z, Wang Z, Kang X. Bradykinin protects nucleus pulposus cells from tert-butyl hydroperoxide-induced damage and delays intervertebral disc degeneration. Int Immunopharmacol 2024; 134:112161. [PMID: 38728878 DOI: 10.1016/j.intimp.2024.112161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 04/23/2024] [Accepted: 04/24/2024] [Indexed: 05/12/2024]
Abstract
Intervertebral disc degeneration (IVDD) is a leading cause of degenerative spinal disorders, involving complex biological processes. This study investigates the role of the kallikrein-kinin system (KKS) in IVDD, focusing on the protective effects of bradykinin (BK) on nucleus pulposus cells (NPCs) under oxidative stress. Clinical specimens were collected, and experiments were conducted using human and rat primary NPCs to elucidate BK's impact on tert-butyl hydroperoxide (TBHP)-induced oxidative stress and damage. The results demonstrate that BK significantly inhibits TBHP-induced NPC apoptosis and restores mitochondrial function. Further analysis reveals that this protective effect is mediated through the BK receptor 2 (B2R) and its downstream PI3K/AKT pathway. Additionally, BK/PLGA sustained-release microspheres were developed and validated in a rat model, highlighting their potential therapeutic efficacy for IVDD. Overall, this study sheds light on the crucial role of the KKS in IVDD pathogenesis and suggests targeting the B2R as a promising therapeutic strategy to delay IVDD progression and promote disc regeneration.
Collapse
Affiliation(s)
- Xiaoming Qiu
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Gansu provincial hospital of TCM (The First Affiliated Hospital of Gansu University of Chinese Medicine), Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Chongwen Ma
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Zhangbin Luo
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Yibao Zhang
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Jihe Kang
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Daxue Zhu
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Zhaoheng Wang
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Lei Li
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Ziyan Wei
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Zhuanping Wang
- Department of endocrinology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China
| | - Xuewen Kang
- Department of Orthopedics, Lanzhou University Second Hospital, The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou, Gansu 730000, China.
| |
Collapse
|
2
|
Wong HH, Seet SH, Bascom CC, Isfort RJ, Bard F. Tonic repression of Collagen I by the Bradykinin receptor 2 in skin fibroblasts. Matrix Biol 2023; 118:110-128. [PMID: 36924903 DOI: 10.1016/j.matbio.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 03/06/2023] [Accepted: 03/06/2023] [Indexed: 03/18/2023]
Abstract
Imbalance of collagen I expression results in severe pathologies. Apart from activation by the TGFβ-receptor/Smad pathway, control of collagen I expression remains poorly understood. Here, we used human dermal fibroblasts expressing a mCherry fluorescent protein driven by endogenous COL1A1 promoter to functionally screen the kinome and phosphatome. We identify 8 negative regulators, revealing that collagen is under tonic repression. The cell surface receptor BDKRB2 represses collagen I and other pro-fibrotic genes. Interestingly, it also promotes other basal membrane ECM genes. This function is independent of the natural ligand, bradykinin, and of SMAD2/3 factors, instead requiring constant ERK1/2 repression. TGFβ stimulation induces rapid BDKRB2 transcriptional downregulation. Human fibrotic fibroblasts have reduced BDKRB2 levels and enhancing its expression in keloid fibroblasts represses COL1A1. We propose that tonic signalling by BDKRB2 prevents collagen overproduction in skin fibroblasts.
Collapse
Affiliation(s)
- Hui Hui Wong
- Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673
| | - Sze Hwee Seet
- Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673
| | - Charles C Bascom
- The Procter & Gamble Company, 8700 Mason-Montgomery Road, Cincinnati, OH 45040, USA
| | - Robert J Isfort
- The Procter & Gamble Company, 8700 Mason-Montgomery Road, Cincinnati, OH 45040, USA
| | - Frederic Bard
- Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673; Centre de Recherche en Cancérologie de Marseille, CRCM, Aix Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes, Equipe Leader Fondation ARC 2021, 13009, Marseille, France..
| |
Collapse
|
3
|
Cárdenas A, Campos J, Ehrenfeld P, Mezzano S, Ruiz-Ortega M, Figueroa CD, Ardiles L. Up-regulation of the kinin B2 receptor pathway modulates the TGF-β/Smad signaling cascade to reduce renal fibrosis induced by albumin. Peptides 2015; 73:7-19. [PMID: 26256678 DOI: 10.1016/j.peptides.2015.08.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 07/09/2015] [Accepted: 08/04/2015] [Indexed: 12/24/2022]
Abstract
The presence of high protein levels in the glomerular filtrate plays an important role in renal fibrosis, a disorder that justifies the use of animal models of experimental proteinuria. Such models have proved useful as tools in the study of the pathogenesis of chronic, progressive renal disease. Since bradykinin and the kinin B2 receptor (B2R) belong to a renoprotective system with mechanisms still unclarified, we investigated its anti-fibrotic role in the in vivo rat model of overload proteinuria. Upon up-regulating the kinin system by a high potassium diet we observed reduction of tubulointerstitial fibrosis, decreased renal expression of α-smooth muscle actin (α-SMA) and vimentin, reduced Smad3 phosphorylation and increase of Smad7. These cellular and molecular effects were reversed by HOE-140, a specific B2R antagonist. In vitro experiments, performed on a cell line of proximal tubular epithelial cells, showed that high concentrations of albumin induced expression of mesenchymal biomarkers, in concomitance with increases in TGF-β1 mRNA and its functionally active peptide, TGF-β1. Stimulation of the tubule cells by bradykinin inhibited the albumin-induced changes, namely α-SMA and vimentin were reduced, and cytokeratin recovered together with increase in Smad7 levels and decrease in type II TGF-β1 receptor, TGF-β1 mRNA and its active fragment. The protective changes produced by bradykinin in vitro were blocked by HOE-140. The development of stable bradykinin analogues and/or up-regulation of the B2R signaling pathway may prove value in the management of chronic renal fibrosis in progressive proteinuric renal diseases.
Collapse
Affiliation(s)
- Areli Cárdenas
- Department of Nephrology, Universidad Austral de Chile, Valdivia, Chile
| | - Javiera Campos
- Department of Nephrology, Universidad Austral de Chile, Valdivia, Chile
| | - Pamela Ehrenfeld
- Department of Anatomy, Histology and Pathology, Universidad Austral de Chile, Valdivia, Chile
| | - Sergio Mezzano
- Department of Nephrology, Universidad Austral de Chile, Valdivia, Chile
| | - Marta Ruiz-Ortega
- IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Carlos D Figueroa
- Department of Anatomy, Histology and Pathology, Universidad Austral de Chile, Valdivia, Chile
| | - Leopoldo Ardiles
- Department of Nephrology, Universidad Austral de Chile, Valdivia, Chile.
| |
Collapse
|
4
|
Tsubakihara Y, Hikita A, Yamamoto S, Matsushita S, Matsushita N, Oshima Y, Miyazawa K, Imamura T. Arkadia enhances BMP signalling through ubiquitylation and degradation of Smad6. J Biochem 2015; 158:61-71. [PMID: 25762727 DOI: 10.1093/jb/mvv024] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 01/17/2015] [Indexed: 02/02/2023] Open
Abstract
Arkadia, a positive regulator of Smad-dependent signalling via the transforming growth factor-β (TGF-β) family, is an E3 ubiquitin ligase that induces ubiquitylation and proteasome-dependent degradation of TGF-β suppressors such as Smad7, c-Ski and SnoN. In this study, we examined the effects of Arkadia on bone morphogenetic protein (BMP)-induced osteoblast differentiation. Knockdown of Arkadia reduced mineralization and expression of osteoblast differentiation markers. Furthermore, we showed that Smad6, a BMP-specific inhibitory Smad, is a target of Arkadia: wild-type (WT) Arkadia, but not the C937A (CA) mutant lacking E3 ubiquitin-ligase activity, induced ubiquitylation and proteasome-dependent degradation of Smad6. Accordingly, protein levels of Smad6, Smad7 and c-Ski were elevated in MEFs from Arkadia KO mice. Finally, expression of Arkadia attenuated blockade of BMP signalling by Smad6 in a transcriptional reporter assay. These results demonstrate that Smad6 is a novel target of Arkadia, and that Arkadia positively regulates BMP signalling via degradation of Smad6, Smad7 and c-Ski/SnoN.
Collapse
Affiliation(s)
- Yutaro Tsubakihara
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Atsuhiko Hikita
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Shin Yamamoto
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Sachi Matsushita
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Natsuki Matsushita
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Yusuke Oshima
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-im
| | - Keiji Miyazawa
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
| | - Takeshi Imamura
- Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-imaging, Proteo-Science Center, Ehime University, Shitsukawa, Toon, Ehime; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Tokyo; Department of Gastroenterology and Metabiology, Ehime University, Shitsukawa, Toon, Ehime; Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime; and Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime; Division of Bio-im
| |
Collapse
|
5
|
Hofman ZLM, Relan A, Hack CE. C-reactive protein levels in hereditary angioedema. Clin Exp Immunol 2014; 177:280-6. [PMID: 24588117 DOI: 10.1111/cei.12314] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/14/2014] [Indexed: 01/10/2023] Open
Abstract
Hereditary angioedema (HAE) patients experience recurrent episodes of angioedema attacks that can be painful, disfiguring and even life-threatening. The disorder results from a mutation in the gene that controls the synthesis of C1-inhibitor (C1INH). C1INH is a major regulator of activation of the contact system. It is often assumed that attacks results from uncontrolled local activation of the contact system with subsequent formation of bradykinin. To evaluate the involvement of inflammatory reactions in HAE, we analysed C-reactive protein (CRP) levels. HAE patients included in a clinical database of recombinant human C1-inhibitor (rhC1INH) studies were evaluated. For the current study we analysed CRP levels when patients were asymptomatic, during a clinical attack and in a follow-up period, and correlated these with the clinical manifestations of the attack. Data from 68 HAE patients were analysed and included CRP levels on 273 occasions. While asymptomatic, 20% of the patients analysed had increased CRP. At the onset of the attack (P = 0·049) and during the next 24 h CRP rose significantly (P = 0·002) in patients with an abdominal location, and post-attack levels were significantly higher in these patients than in patients with attacks at other locations (P = 0·034). In conclusion, CRP levels are elevated in a substantial proportion of asymptomatic HAE patients. Levels of CRP increase significantly during an abdominal attack. These data suggest low-grade systemic inflammatory reactions in HAE patients as well as a triggering event for attacks that starts prior to symptom onset.
Collapse
Affiliation(s)
- Z L M Hofman
- Laboratory for Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | | | | |
Collapse
|
6
|
Takano M, Matsuyama S. Intracellular and nuclear bradykinin B2 receptors. Eur J Pharmacol 2014; 732:169-72. [DOI: 10.1016/j.ejphar.2014.03.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 03/06/2014] [Accepted: 03/10/2014] [Indexed: 01/11/2023]
|
7
|
da Costa PLN, Sirois P, Tannock IF, Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2013; 345:27-38. [PMID: 24333733 DOI: 10.1016/j.canlet.2013.12.009] [Citation(s) in RCA: 90] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 11/29/2013] [Accepted: 12/02/2013] [Indexed: 12/20/2022]
Abstract
Kinins are generated within inflammatory tissue microenvironments, where they exert diverse functions, including cell proliferation, leukocyte activation, cell migration, endothelial cell activation and nociception. These pleiotropic functions depend on signaling through two cross talking receptors, the constitutively expressed kinin receptor 2 (B2R) and the inducible kinin receptor 1 (B1R). We have reviewed evidence, which supports the concept that kinin receptors, especially kinin receptor 1, are promising targets for cancer therapy, since (1) many tumor cells express aberrantly high levels of these receptors; (2) some cancers produce kinins and use them as autocrine factors to stimulate their growth; (3) activation of kinin receptors leads to activation of macrophages, dendritic cells and other cells from the tumor microenvironment; (4) kinins have pro-angiogenic properties; (5) kinin receptors have been implicated in cancer migration, invasion and metastasis; and (6) selective antagonists for either B1R or B2R have shown anti-proliferative, anti-inflammatory, anti-angiogenic and anti-migratory properties. The multiple cross talks between kinin receptors and renin-angiotensin system (RAS) as well as its implications for targeting KKS or RAS for the treatment of malignancies are also discussed. It is expected that B1R antagonists would interfere less with housekeeping functions and therefore would be attractive compounds to treat selected types of cancer. Reliable clinical studies are needed to establish the translatability of these data to human settings and the usefulness of kinin receptor antagonists.
Collapse
Affiliation(s)
- Patrícia L N da Costa
- Laboratório de Oncologia Experimental, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Pierre Sirois
- CHUL Research Center, Laval University, Quebec City, Canada
| | - Ian F Tannock
- Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
| | - Roger Chammas
- Laboratório de Oncologia Experimental, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil.
| |
Collapse
|
8
|
Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways. Eur J Pharmacol 2013; 710:100-9. [PMID: 23588115 DOI: 10.1016/j.ejphar.2013.03.048] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2012] [Revised: 03/21/2013] [Accepted: 03/28/2013] [Indexed: 02/05/2023]
Abstract
Bradykinin drives normal lung fibroblasts into myofibroblasts, induces fibroblast proliferation and activates mitogen activated protein kinase pathways (MAPK) but its effects on bronchial fibroblasts from asthmatics (HBAFb) have not been yet studied. We studied bradykinin-induced fibroblast proliferation and differentiation and the related intracellular mechanisms in HBAFb compared to normal bronchial fibroblasts (HNBFb). Bradykinin-stimulated HBAFb and HNBFb were used to assess: bradykinin B2 receptor expression by Western blot analysis; cell proliferation by [(3)H] thymidine incorporation; α-smooth muscle actin (SMA) expression/polymerization by Western blot and immunofluorescence; epidermal growth factor (EGF) receptor, extracellular-regulated kinase (ERK) 1/2 and p38 MAPK activation by immunoprecipitation and Western blot, respectively. Constitutive bradykinin B2 receptor and α-SMA expression was higher in HBAFb as compared to HNBFb. Bradykinin increased bradykinin B2 receptor expression in HBAFb. Bradykinin, via bradykinin B2 receptor, significantly increased fibroblast proliferation at lower concentration (10(-11)M) and α-SMA expression/polymerization at higher concentration (10(-6)M) in both cells. Bradykinin increased ERK1/2 and p38 phosphorylation via bradykinin B2 receptor; EGF receptor inhibitor AG1478 and panmetalloproteinase inhibitor GM6001 blocked bradykinin-induced ERK1/2 activation but not p38 phosphorylation. Bradykinin, via bradykinin B2 receptor, induced EGF receptor phosphorylation that was suppressed by AG1478. In HBAFb AG1478, GM6001, the ERK1/2-inhibitor U0126 and the p38 inhibitor SB203580 suppressed bradykinin-induced cell proliferation, but only SB203580 reduced myofibroblast differentiation. These data indicate that bradykinin is actively involved in asthmatic bronchial fibroblast proliferation and differentiation, through MAPK pathways and EGF receptor transactivation, by which bradykinin may contribute to airway remodeling in asthma, opening new horizons for potential therapeutic implications in asthmatic patients.
Collapse
|
9
|
Feierler J, Wirth M, Welte B, Schüssler S, Jochum M, Faussner A. Helix 8 plays a crucial role in bradykinin B(2) receptor trafficking and signaling. J Biol Chem 2011; 286:43282-93. [PMID: 22016392 DOI: 10.1074/jbc.m111.256909] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Upon activation the human bradykinin B(2) receptor (B(2)R) acts as guanine nucleotide exchange factor for the G proteins G(q/11) and G(i). Thereafter, it gets phosphorylated by G protein-coupled receptor kinases (GRKs) and recruits β-arrestins, which block further G protein activation and promote B(2)R internalization via clathrin-coated pits. As for most G protein-coupled receptors of family A, an intracellular helix 8 after transmembrane domain 7 is also predicted for the B(2)R. We show here that disruption of helix 8 in the B(2)R by either C-terminal truncation or just by mutation of a central amino acid (Lys-315) to a helix-breaking proline resulted in strong reduction of surface expression. Interestingly, this malfunction could be overcome by the addition of the membrane-permeable B(2)R antagonist JSM10292, suggesting that helix 8 has a general role for conformational stabilization that can be accounted for by an appropriate antagonist. Intriguingly, an intact helix 8, but not the C terminus with its phosphorylation sites, was indispensable for receptor sequestration and for interaction of the B(2)R with GRK2/3 and β-arrestin2 as shown by co-immunoprecipitation. Recruitment of β-arrestin1, however, required the presence of the C terminus. Taken together, our results demonstrate that helix 8 of the B(2)R plays a crucial role not only in efficient trafficking to the plasma membrane or the activation of G proteins but also for the interaction of the B(2)R with GRK2/3 and β-arrestins. Additional data obtained with chimera of B(2)R with other G protein-coupled receptors of family A suggest that helix 8 might have similar functions in other GPCRs as well.
Collapse
Affiliation(s)
- Jens Feierler
- Abteilung für Klinische Chemie und Klinische Biochemie, Ludwig-Maximilians-Universität, Nussbaumstrasse 20, D-80336 München, Germany
| | | | | | | | | | | |
Collapse
|
10
|
Cavanaugh A, McKenna J, Stepanchick A, Breitwieser GE. Calcium-sensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retention. J Biol Chem 2010; 285:19854-64. [PMID: 20421307 DOI: 10.1074/jbc.m110.124792] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Metabolic labeling with [(35)S]cysteine was used to characterize early events in CaSR biosynthesis. [(35)S]CaSR is relatively stable (half-life approximately 8 h), but maturation to the final glycosylated form is slow and incomplete. Incorporation of [(35)S]cysteine is linear over 60 min, and the rate of [(35)S]CaSR biosynthesis is significantly increased by the membrane-permeant allosteric agonist NPS R-568, which acts as a cotranslational pharmacochaperone. The [(35)S]CaSR biosynthetic rate also varies as a function of conformational bias induced by loss- or gain-of-function mutations. In contrast, [(35)S]CaSR maturation to the plasma membrane was not significantly altered by exposure to the pharmacochaperone NPS R-568, the allosteric agonist neomycin, or the orthosteric agonist Ca(2+) (0.5 or 5 mm), suggesting that CaSR does not control its own release from the endoplasmic reticulum. A CaSR chimera containing the mGluR1alpha carboxyl terminus matures completely (half-time of approximately 8 h) and without a lag period, as does the truncation mutant CaSRDelta868 (half-time of approximately 16 h). CaSRDelta898 exhibits maturation comparable with full-length CaSR, suggesting that the CaSR carboxyl terminus between residues Thr(868) and Arg(898) limits maturation. Overall, these results suggest that CaSR is subject to cotranslational quality control, which includes a pharmacochaperone-sensitive conformational checkpoint. The CaSR carboxyl terminus is the chief determinant of intracellular retention of a significant fraction of total CaSR. Intracellular CaSR may reflect a rapidly mobilizable "storage form" of CaSR and/or may subserve distinct intracellular signaling roles that are sensitive to signaling-dependent changes in endoplasmic reticulum Ca(2+) and/or glutathione.
Collapse
Affiliation(s)
- Alice Cavanaugh
- Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania 17822, USA
| | | | | | | |
Collapse
|
11
|
Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, Renné T, Kleinschnitz C. Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema. Stroke 2009; 40:285-93. [DOI: 10.1161/strokeaha.108.526673] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Madeleine Austinat
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Stefan Braeuninger
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - João B. Pesquero
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Marc Brede
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Michael Bader
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Guido Stoll
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Thomas Renné
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| | - Christoph Kleinschnitz
- From Department of Neurology (M.A., S.B., G.S., C.K.), Department of Anesthesiology (M.Brede), and Institute for Clinical Biochemistry and Pathobiochemistry (T.R.), University of Würzburg, Würzburg, Germany; Departamento de Biofisica (J.B.P.), Universidade Federal de São Paulo, São Paulo, Brazil; Max-Delbrück-Center for Molecular Medicine (M.Bader), Berlin-Buch, Germany
| |
Collapse
|
12
|
Bengtson SH, Eddleston J, Mörgelin M, Zuraw BL, Herwald H. Regulation of kinin B2 receptors by bradykinin in human lung cells. Biol Chem 2008; 389:1435-40. [DOI: 10.1515/bc.2008.159] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractBradykinin is a potent mediator of inflammation that has been shown to participate in allergic airway inflammation. The biologic effects of bradykinin are mediated by binding and activation of its cognate receptor, the B2receptor (B2R). In the lung fibroblast cell line IMR-90, binding of bradykinin to B2R triggers down-regulation of receptor surface expression, suggesting that bradykinin-induced inflammation is transient and self-limited. Notably, subjects with chronic airway inflammation continue to respond to BK following a first challenge. B2Rs are expressed on many different lung cell types, including airway epithelial cells. We therefore compared IMR-90 cells with the human lung epithelial cell line BEAS2B and found that B2R expression in the two cell types is differently regulated by BK. Whereas BK induces down-regulation of B2R in IMR-90 cells, the same treatment leads to up-regulation of the receptor in BEAS2B cells. These results provide a possible explanation for the potency of bradykinin in inducing ongoing airway inflammation.
Collapse
|
13
|
Scharfstein J, Lima APCA. Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi. Subcell Biochem 2008; 47:140-154. [PMID: 18512348 DOI: 10.1007/978-0-387-78267-6_11] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Trypanosoma cruzi trypomastigotes rely on the structural diversity of the cruzipain family of cysteine proteases to infect and multiply in nonprofessional phagocytic cells. Herein, we will review studies demonstrating that the interplay of cruzipain with peptidase inhibitors modulate infection outcome in a variety of experimental settings. Studies with a panel of T. cruzi strains showed that parasite ability to invade human smooth muscle cells is influenced by the balance between cruzipain and chagasin, a tight binding endogenous inhibitor of papain-like cysteine proteases. Analysis of T. cruzi interaction with endothelial cells and cardiomyocytes indicated that parasite-induced activation of bradykinin receptors drive host cell invasion by [Ca2+]I-dependent pathways. Clues about the mechanisms underlying kinin generation in vivo by trypomastigotes came from analysis of the dynamics of edematogenic inflammation. Owing to plasma extravasation, the blood-borne kininogens accumulate in peripheral sites of infection. Upon diffusion in peripheral tissues, kininogens (i.e., type III cystatins) bind to heparan sulphate chains, thus constraining interactions of the cystatin-like inhibitory domains with cruzipain. The cell bound kininogens are then turned into facile substrates for cruzipain, which liberates kinins in peripheral tissues. Subjected to tight-regulation by kinin-degrading metallopeptidases, such as angiotensin converting enzyme, the short-lived kinin peptides play a dual role in the host-parasite balance. Rather than unilaterally stimulating pathogen infectivity via bradykinin receptors, the released kinins potently induce dendritic cell maturation, thus stimulating type 1 immune responses. In conclusion, the studies reviewed herein illustrate how regulation of parasite proteases may affect host-parasite equilibrium in the course of IT cruzi infection.
Collapse
Affiliation(s)
- Julio Scharfstein
- Lnstituto de Biofisica Carlos Chagas Filho, UFRJ, Rio de Janeiro, Brazil.
| | | |
Collapse
|
14
|
Shukla AK, Haase W, Reinhart C, Michel H. Heterologous expression and characterization of the recombinant bradykinin B2 receptor using the methylotrophic yeast Pichia pastoris. Protein Expr Purif 2007; 55:1-8. [PMID: 17711791 DOI: 10.1016/j.pep.2007.02.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2006] [Revised: 02/14/2007] [Accepted: 02/16/2007] [Indexed: 11/22/2022]
Abstract
The human bradykinin subtype 2 receptor (B(2)R), a member of class A GPCRs, was heterologously expressed in the methylotrophic yeast Pichia pastoris. The recombinant receptor was produced as a fusion protein with affinity tags and it was expressed at a level of 3.5 pmol/mg of total membrane protein. [(3)H]Bradykinin binding analysis revealed that the recombinant receptor binds to its endogenous ligand bradykinin with high affinity (K(d)=0.87+/-0.1 nM), similar to the native receptor. Enzymatic deglycosylation revealed that the recombinant B(2)R was produced in a glycosylated form. Immunogold staining of the Pichia cells expressing B(2)R suggested that the recombinant receptor was localized intracellularly and it was not present in the plasma membrane. The data presented here should facilitate isolation of the recombinant receptor for structural studies.
Collapse
Affiliation(s)
- Arun Kumar Shukla
- Department of Molecular Membrane Biology, Max Planck Institute of Biophysics, Max-von-Laue Str. 3, 60438 Frankfurt am Main, Germany.
| | | | | | | |
Collapse
|
15
|
Pawluczyk IZA, Patel SR, Harris KPG. Pharmacological enhancement of the kallikrein-kinin system promotes anti-fibrotic responses in human mesangial cells. Cell Physiol Biochem 2007; 18:327-36. [PMID: 17170519 DOI: 10.1159/000097610] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/10/2006] [Indexed: 11/19/2022] Open
Abstract
The aim of the present study was to investigate whether pharmacological enhancement of the renal kallikrein-kinin system using the vasopeptidase inhibitor omapatrilat plays a direct role in modulating the fibrotic responses of human mesangial cells to injury. Treatment with 40 micromol/L omapatrilat was able to reduce macrophage-conditioned medium (MPCM)-induced fibronectin levels without affecting mRNA expression. MPCM injury also suppressed kallikrein and low molecular weight kininogen mRNA. Omapatrilat was able to attenuate this suppression. Bradykinin levels in contrast were increased by MPCM and treatment with omapatrilat further augmented levels. Co-incubation with the bradykinin B2 receptor antagonist HOE 140 attenuated the omapatrilat-induced lowering of fibronectin. Moreover, inhibition of cGMP release had a similar effect. Paradoxically, RT-PCR and Southern blotting demonstrated that bradykinin B2 receptor mRNA levels were down regulated in response to omapatrilat. Western blotting supported this data. Supernatant levels of tissue plasminogen activator (tPA), a product of bradykinin stimulation, were decreased by omapatrilat while cell associated tPA levels were increased. Matrix metalloproteinase-9 (MMP-9) mRNA expression was up regulated by omapatrilat treatment, although no difference in active zymogen levels was observed. In conclusion enhancement of kallikrein-kinin system appears to play a direct role in promoting anti-fibrotic responses in MPCM-injured human mesangial cells.
Collapse
|
16
|
Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 2005; 26:1292-300. [PMID: 15878794 DOI: 10.1016/j.peptides.2005.03.050] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Bradykinin is an important modulator of endothelial cell function and has also a powerful cardioprotective effect. Here we report that treatment of severely pulmonary hypertensive rats (that recapitulate several of the physiological and pathological characteristics of the human pulmonary vascular disease, including dramatic right ventricular hypertrophy, pericardial effusion and death) with a newly synthesized long-acting bradykinin B2 receptor agonist B9972 caused reduction of the pulmonary artery pressure (PAP=51+/-2.0 versus 68+/-2.8 of untreated animals) and of right ventricular hypertrophy (Rv/Lv+S=0.55+/-0.02 versus 0.73+/-0.03 of untreated rats) and activation of Akt. Long-term stimulation with B9972 in our animal model of SPH resulted in decreased expression of the B2 receptor in lung vasculature. Treatment with B9972 decreased the number of plexiform lesions in the lungs by inducing cell apoptosis in the obliterated vessels and by restoring caveolin-1 expression. B9972 also promoted eNOS activation. In vitro B9972 caused activation of caspase-3 as well as Erk and induction of prostacyclin production in rat pulmonary microvascular EC. Taken together our data suggest that a stable bradykinin B2 agonist B9972 demonstrates the capacity to reduce severe pulmonary hypertension, right ventricular hypertrophy and induce apoptosis of hyperproliferative cells in pre-capillary pulmonary arterioles.
Collapse
Affiliation(s)
- Laimute Taraseviciene-Stewart
- Pulmonary Hypertension Center, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Box C272, 4200 East Ninth Avenue, Denver, CO 80262, USA
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Suvorova ES, Gripentrog JM, Miettinen HM. Different Endocytosis Pathways of the C5a Receptor and the N-formyl Peptide Receptor. Traffic 2004; 6:100-15. [PMID: 15634211 DOI: 10.1111/j.1600-0854.2004.00256.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Two chemoattractant receptors, C5aR (the complement fragment C5a receptor) and FPR (the N-formyl peptide receptor), are involved in neutrophil activation at sites of inflammation. In this study, we found major differences in the intracellular trafficking of the receptors in transfected Chinese hamster ovary (CHO) cells. Western blot analysis showed that FPR was stable during a 3 h stimulation with ligand, but C5aR was reduced in quantity by 50%. Not all C5aR was targeted directly for degradation however; a small, but visible fraction of the receptor became re-phosphorylated upon subsequent addition of ligand, suggesting that some of the receptor had cycled to the cell surface. Light membrane fractions isolated from activated cells showed C5aR distribution at the bottom of a glycerol gradient, colocalizing with the main distribution of the late endosomal/lysosomal marker LAMP2, whereas FPR was found at the bottom of the gradient as well as in the middle of the gradient, where it cofractionated with the early/sorting endosomal marker Rab5. Using fluorescence microscopy, we observed ligand-dependent redistribution of C5aR-EGFP from the plasma membrane to LAMP2-positive compartments, whereas FPR-EGFP showed significant colocalization with the early/sorting endosomes. Analysis of endogenous C5aR and FPR in neutrophils revealed a pattern similar to the CHO transfectants: C5aR underwent degradation after prolonged ligand stimulation, while FPR did not. Finally, we confirmed the down-regulation of C5aR in a functional assay by showing reduced chemotaxis toward C5a in both CHO transfectants and neutrophils after preincubation with C5a. A similar decrease in FPR-mediated chemotaxis was not observed.
Collapse
Affiliation(s)
- Elena S Suvorova
- Department of Microbiology, Montana State University, Bozeman, MT 59717-3520, USA
| | | | | |
Collapse
|
18
|
Kang DS, Ryberg K, Mörgelin M, Leeb-Lundberg LMF. Spontaneous Formation of a Proteolytic B1 and B2 Bradykinin Receptor Complex with Enhanced Signaling Capacity. J Biol Chem 2004; 279:22102-7. [PMID: 15033977 DOI: 10.1074/jbc.m402572200] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
B1 bradykinin receptor (B1R) induction is critical in the adaptation of the kinin-mediated inflammatory response from a B2 bradykinin receptor (B2R) subtype to a B1R subtype that occurs during chronic insult. Here, we show that B1R spontaneously forms a proteolytic plasma membrane complex with B2R along with increased receptor signaling capacity. Co-expression of hemagglutinin-tagged B2R with FLAG-tagged B1R in HEK293 cells resulted in degradation of B2R as determined by the diminution of the intact 65-kDa B2R species and the appearance of proteolytic B2R products at 30-40 kDa and by the reduction in B2R bradykinin binding sites. On the other hand, the 35-kDa B1R remained intact. Receptor co-expression also led to an increase in constitutive and agonist-stimulated receptor signaling. Selective immunoprecipitation with epitope-specific antibodies revealed a spontaneously formed heterologous receptor complex, which was composed of the intact 35-kDa B1R and the B2R degradation products. Cellular fractionation, cell surface biotinylation, and immunoelectron microscopy showed that B2R.B1R complexes were present on the cell surface. This is the first evidence that a heterologous G protein-coupled receptor complex in the plasma membrane is linked to proteolytic degradation of a participating receptor, and this mechanism may contribute to the adaptation of the kinin response from a B2 type to a B1 type during chronic insult.
Collapse
Affiliation(s)
- Dong Soo Kang
- Department of Physiological Sciences, Lund University, Lund SE-22184, Sweden
| | | | | | | |
Collapse
|
19
|
Skidgel RA, Alhenc-Gelas F, Campbell WB. Prologue: kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003; 284:H1886-91. [PMID: 12742820 DOI: 10.1152/ajpheart.00164.2003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Randal A Skidgel
- Department of Pharmaocolgy, University of Illinois College of Medicine, Chicago 60612, USA
| | | | | |
Collapse
|